Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03004287 · ClinicalTrials.gov registry record · Phase 2

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

A Phase 2 study of Multiple Myeloma, sponsored by University of Arkansas.

Active
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT03004287 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 50 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03004287, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Arkansas.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Cisplatin
  • DRUG Dexamethasone
  • DRUG Daratumumab
  • DRUG Carfilzomib
  • DRUG Thalidomide

Study Locations (1)

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2017-07-01
Est. Completion 2027-10
Phase Phase 2

Sponsor

University of Arkansas

318 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03004287

The ClinicalTrials.gov registry entry for NCT03004287 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.

NCT03004287 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.

Frequently Asked Questions

What is clinical trial NCT03004287 about?

NCT03004287 is a clinical study titled "2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy". This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects

What is the current status of trial NCT03004287?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2017-07-01. Estimated completion is 2027-10.

What conditions does trial NCT03004287 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT03004287?

The interventions under investigation include: Cisplatin (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), Thalidomide (DRUG).

Who is sponsoring clinical trial NCT03004287?

This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03004287 being conducted?

This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.